{"name":"Sanifit Therapeutics S. A.","slug":"sanifit-therapeutics-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Experimental: SNF472","genericName":"Experimental: SNF472","slug":"experimental-snf472","indication":"Hyperphosphatemia in patients with chronic kidney disease on hemodialysis","status":"phase_3"}]}],"pipeline":[{"name":"Experimental: SNF472","genericName":"Experimental: SNF472","slug":"experimental-snf472","phase":"phase_3","mechanism":"SNF472 is a calcimimetic agent that binds to and activates the calcium-sensing receptor to reduce serum phosphate levels in patients with chronic kidney disease.","indications":["Hyperphosphatemia in patients with chronic kidney disease on hemodialysis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQM3BKWDI5QWVabl9QYVc4X2hmZTRGMFNvN2V0R2VpMlRZVkFCVDRZejFsWWV2eTZfXzhEMF9yMzVQZmx3akRXTEdLOWV4RjFYdEJfVG1XM2tVWS1CclUwbHNyUEo4TjZBR1JrRE9wYnhDT2xnN3hFZlp4NXRPY1I4UEttUkwyRmly?oc=5","date":"2023-10-27","type":"pipeline","source":"EU-Startups","summary":"101 Top Medical Startups and Companies in Spain (2021) - EU-Startups","headline":"101 Top Medical Startups and Companies in Spain (2021) - EU","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPRW9HaWc2Z0FSX0FsNFFVUlFtZkFJdHJYS3A3em9VMV81ekdoSm5nQVNCWXljdG9zMk1TZWp4ay1fdHM1OFNIRkxLSjB3WHhkalBnX0VVci02aFNUYkQ0bEs4aXM3WlVXNnVzdEhxNFRCUDIxZVBhLTlpUHNxWDE2Yl9JalJGUUp3LVBGSU5DSTQwZlZiYVJSRlZqQXhzZ1Y4ZmRVY2JELVpMY1VDcEE?oc=5","date":"2021-11-23","type":"pipeline","source":"Iberian Lawyer","summary":"Baker McKenzie advises Sanifit on Vifor Pharma acquisition, counselled by VC Biolaw - Iberian Lawyer","headline":"Baker McKenzie advises Sanifit on Vifor Pharma acquisition, counselled by VC Biolaw","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNM1cxNzhiV1JoQ3Z6dUlSNlNGUkViOUhpNFJ2WS1IaVlPeTI5X0RrSHRwcm5xdkZoVGR0Mm9IY1FlelpFTHpaMlJxVER1TVdBQ3JTeTM5dHljelhkNUM0RnozVnpHTDRJUU84NnBXY2JaVDVvbThXOXRSa2M4UW5DS09sN1N3dllGcm84Y0k1Z1IxRlRrWEYxM0pIY2dvNThqbko2MWVNaW9oUGF4eHY2X1doY3I4RXJLYXc3NXhFWUR5QTA?oc=5","date":"2021-11-22","type":"trial","source":"Fierce Biotech","summary":"Sanifit, having put Spain's biotech scene on the map, lands $231M Vifor buyout ahead of phase 3 data - Fierce Biotech","headline":"Sanifit, having put Spain's biotech scene on the map, lands $231M Vifor buyout ahead of phase 3 data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxNT1dmeVE3QU10SlZGdmgxZ2pRdU5YeThReUd2eTdqZ2VjWVFPSmN4a2dPTzBEclQwTFh4TXhxSzdocmttRHdCMXhCeUhFdGlhdTFHWDNod1BDck96eDBNQnpKQ2pxSFZIR1llY1FfS010M2ZETTlJWkpIWHFRVWtvSmVzQTBaaFdyY1dKWFNPMmJEb2JGOFVvMlFKeGx2Q2otb2FRajZiRXY5YU5fMXZ3SW9vblVCU3NLRmk2eW1OakszN29EU2RIcGRXaTItWU04ZUtGemhaYTdGLW1pRXU1dWpETVctNGFRMlc1cGFoMHg?oc=5","date":"2021-11-22","type":"deal","source":"globenewswire.com","summary":"Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology - globenewswire.com","headline":"Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}